Skin longevity firm lands $20m in growth funding

OneSkin accepts unsolicited approach from growth equity firm to ramp sales of ‘skinspan’ focused products that target senescent cells. Longevity biotech OneSkin has raised an additional $20 million in a Series A round from New York growth equity firm Prelude Growth Partners as it seeks to scale its …